Capstone Therapeutics Corp. (NASDAQ:CAPS) Shares Shorted: Short Interest Up 73.0% in September

Capstone Therapeutics Corp. (NASDAQ:CAPS) was the recipient of a large growth in short interest in the month of September. As of September 15th, there was short interest totaling 92,396 shares, a growth of 73.0% from the August 31st total of 53,416 shares. Currently, 0.7% of the shares of the company are sold short. Based on an average daily volume of 235,825 shares, the days-to-cover ratio is currently 0.4 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut Capstone Therapeutics from a “sell (e+)” rating to a “sell (e)” rating in a research note on Tuesday, September 22nd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Capstone Therapeutics has a consensus rating of “Sell”.

Capstone Therapeutics Stock Performance

NASDAQ:CAPS opened at $0.15 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.99 and a quick ratio of 0.39. The business has a fifty day simple moving average of $0.20 and a two-hundred day simple moving average of $0.33. Capstone Therapeutics has a 1 year low of $0.14 and a 1 year high of $1.44. The company has a market capitalization of $3.07 million, a P/E ratio of -0.04 and a beta of -1.49.

About Capstone Therapeutics

Capstone Therapeutics Corporation was a U.S.-based biotechnology company focused on developing peptide-based therapies for diseases involving fibrosis, scarring and abnormal tissue repair. Publicly available information about the company’s current operations is limited.

Its principal disclosed product candidate was AZX100, a synthetic peptide designed to influence cellular pathways associated with scar formation and fibrotic disease. The candidate was investigated for potential applications involving conditions such as dermal scarring and pulmonary fibrosis, although the available historical information does not establish a currently marketed product.

Capstone Therapeutics was based in the United States and appeared to operate primarily as a development-stage pharmaceutical company rather than as a commercial drug manufacturer.